Scalper1 News
Clinical research organization WuXi PharmaTech (WX) joined the exodus of Chinese companies from the U.S. stock market Friday, announcing that it had agreed to be bought by a Chinese investor consortium for $3.3 billion. WuXi stock was up 5.5% near 43.50 in morning trading on the stock market today. WuXi agreed to officially merge with New WuXi Life Science Limited and its subsidiary WuXi Merger Limited, which were created by a group of investors Scalper1 News
Scalper1 News